Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells

@article{Lioznov2010LenalidomideAS,
  title={Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells},
  author={Michael V Lioznov and J El-cheikh and F. Hoffmann and York Hildebrandt and Francis Ayuketang Ayuk and Christine Wolschke and Djorde Atanackovic and Georgia Schilling and Anita Badbaran and Ulrike Bacher and Boris Fehse and A. R. Zander and Didier Blaise and Mohamad Mohty and Nicolaus Kr{\"o}ger},
  journal={Bone Marrow Transplantation},
  year={2010},
  volume={45},
  pages={349-353}
}
We investigated efficacy and toxicity of lenalidomide in 24 heavily pretreated myeloma patients with a median age of 59 years (range: 37–70) and relapse after allo-SCT. Lenalidomide was given at a dose of 15 mg (n=4), or 25 mg (n=20), orally once daily on day 1 to day 1 every 28 days, with (n=20) or without (n=4) DHAP. The median number of lenalidomide cycles was five (range: 2–17). Major side effects were leukopenia (grade 4: 4%, grade 3: 21% and grade 2: 17%) and thrombocytopenia (grade 3: 17… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 17 references

Similar Papers

Loading similar papers…